| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
27,638 |
7,058 |
$1.38M |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
12,573 |
3,607 |
$147K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,055 |
683 |
$78K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
19,818 |
5,297 |
$20K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
317 |
222 |
$11K |
| 87481 |
|
192 |
168 |
$4K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
169 |
147 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
168 |
146 |
$1K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
169 |
147 |
$674.76 |
| 87640 |
|
126 |
97 |
$578.21 |
| 87529 |
|
73 |
60 |
$522.72 |
| 87625 |
|
73 |
60 |
$300.18 |
| 87511 |
|
73 |
60 |
$261.36 |
| 87563 |
|
73 |
60 |
$261.36 |
| 87653 |
|
73 |
60 |
$261.36 |
| 81231 |
|
16 |
14 |
$0.00 |
| 81226 |
|
16 |
14 |
$0.00 |
| 81230 |
|
16 |
14 |
$0.00 |
| 81227 |
|
16 |
14 |
$0.00 |
| 81225 |
|
16 |
14 |
$0.00 |
| 81381 |
|
17 |
14 |
$0.00 |
| 81479 |
Unlisted molecular pathology procedure |
44 |
14 |
$0.00 |